Current Hepatitis Reports

, Volume 11, Issue 3, pp 146–152

Non-interferon Therapies for Hepatitis C

Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors)

DOI: 10.1007/s11901-012-0133-7

Cite this article as:
Membreno, F.E. & Lawitz, E.J. Curr Hepatitis Rep (2012) 11: 146. doi:10.1007/s11901-012-0133-7


Hepatitis C (HCV) therapy is currently undergoing a revolution with the development of new classes of Direct Acting Antivirals (DAAs) with distinct mechanisms of action, potency, resistance patterns and significantly less side effects compared to current standard of care therapies. Our patients have struggled with interferon based therapies for the last 2 decades, but now we are at a turning point with the development of new non-interferon combinations of DAAs. These new molecules have demonstrated to be effective, safe and most importantly have shown the capacity to achieve a sustained virological response in the absence of interferon. This article summarizes the available published clinical trials that are rapidly contributing to our understanding of how we might need to combine these new antivirals to achieve the highest rates of cure in HCV patients who are treatment naïve, non-responders or cirrhotic, across all genotypes.


Interferon-freeNon-interferonInterferon intolerantRibavirinHCVHepatitis CDirect acting antiviraleDAATegobuvirGS-9190RG7128DanoprevirBI201335BI207127AlisporivirGS-5885GS-9451ABT-450/rABT-072ABT-333RitonavirDaclatasvirGS-7977AsunaprevirDAAs

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Alamo Medical ResearchSan AntonioUSA